Epigenomics AG (ECX F) stock market data APIs
€1.0073
-0.1(-9.9%)
as of January 16, 2026
Try our APIs with
free plan!
Epigenomics AG Financial Data Overview
Price chart is built with
Anychart
Epigenomics AG does not have significant operations. Previously, the company was involved in liquid biopsy for the early detection of cancer. The company was founded in 1998 and is headquartered in Heidelberg, Germany.
Prev. Close
1.0073
Open
0.9038
High
1.0074
Low
0.8964
52 wk Range
0.5-1.6
Market Cap
789 K
Shares Outstanding
877 K
Revenue
4 000
EPS
-6.4
Beta
0.823
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Epigenomics AG data using free add-ons & libraries
Get Epigenomics AG Fundamental Data
Epigenomics AG Fundamental data includes:
- Net Revenue: 4 000
- EBITDA: -1 383 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2016-03-16
- EPS/Forecast: 30.4
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Epigenomics AG News
New
Human Papilloma Virus Testing Market Research Report 2025-2033 Featuring Abbott Laboratories, BioMerieux, Bio-Rad Laboratories, Epigenomics, Siemens Healthineers, Hologic, Qiagen, F. Hoffmann-La Roche
Company Logo The Human Papillomavirus (HPV) Testing Market is projected to grow from USD 1.52 billion in 2024 to USD 3.62 billion by 2033, at a 10.11% CAGR from 2025. This growth is fueled by increas...
New study published in the Journal of the National Cancer Institute concludes that Epi proColon® is the test of choice for the millions of individuals not willing to participate in FIT or colonoscopy screening
Under the primary base case analysis, annual mSEPT9 screening resulted in more Quality-adjusted-life-years gained (QALYG), CRC cases averted and CRC deaths averted than both annual FIT screening and C...
Epigenomics AG Reports on New Micro-Simulation Study Results Published in Cancer Medicine Indicating That Epi proColon® Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer
- Adherence rates and screening intervals recognized as decisive elements of successful screening strategies - BERLIN, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the ...
New Micro-Simulation Study in Cancer Medicine Finds Epi proColon® Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer
- Adherence rates and screening intervals recognized as decisive elements of successful screening strategies - BERLIN, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
